LDC and AstraZeneca Broaden Drug Discovery Alliance
The Lead Discovery Center GmbH (LDC) and AstraZeneca have expanded their alliance to discover new medicines for the treatment of human diseases with high unmet medical need. - April 16, 2015
LDC and HZI Enter Partnership for the Discovery of New Drugs Against Multi-Resistant Bacteria
The Lead Discovery Center GmbH (LDC) and the Helmholtz Centre for Infection Research (HZI) will be working in close cooperation to identify and optimize new drug candidates against methicillin-resistant Staphylococcus aureus (MRSA). MRSA are resistant to several traditional broad-spectrum... - April 03, 2015
LDC Receives 1 Million Euros from the Max Planck Foundation
The Lead Discovery Center receives one million euros from the Max Planck Foundation for the development of new drug candidates. - March 12, 2015
LDC and The Arctic University of Norway Collaborate to Discover New Medicines from the Arctic Ocean
The Lead Discovery Center GmbH (LDC), a renowned translational research organization, and UiT The Arctic University of Norway (UiT) have teamed up to discover new medicines from the marine arctic environment. - October 13, 2014
LDC Enters First Collaboration with the Helmholtz Association
New cancer therapy approach from the German Cancer Consortium (DKTK). - October 11, 2014
LDC Forms Early Drug Discovery Alliance with Daiichi Sankyo
Utilizing shared compound libraries for novel LDC targets. - April 19, 2014
Hit Discovery Constance GmbH: A New European hub for HTS and Compound Management
Today Hit Discovery Constance GmbH ("HDC"), a new joint venture organisation between Lead Discovery Center (Dortmund/Germany), Centre for Drug Design and Discovery (CD3, KULeuven, Leuven/Belgium) and Axxam (Milan/Italy) has started its operation. The new company is based in Constance... - January 17, 2014
Lead Discovery Center GmbH Announces Five-Year Strategic Partnership with Merck Serono
Partners will collaborate to discover lead structures and potential development candidates for novel drug targets. - November 02, 2013
MPI of Biochemistry, LDC and Qurient Close License Deal on a New Compound Against Metastatic Cancers
The Max Planck Institute of Biochemistry (MPIB), the Lead Discovery Center GmbH (LDC) and Qurient Co., Ltd have entered into a license agreement providing Qurient with world-wide, exclusive rights to a new kinase inhibitor for the treatment of metastatic cancer. The lead compound belongs to a... - March 14, 2013
LDC Forms Drug Discovery Alliance with AstraZeneca
The Lead Discovery Center GmbH (LDC) and AstraZeneca have joined forces to discover new medicines for the treatment of human diseases with high unmet medical need. Through a two-year collaboration, AstraZeneca will add 250,000 high-quality compounds to LDC's internal screening collection to pursue... - February 02, 2013